What is the “rolapitant synthesis” patent, and what is it protecting?
Rolapitant is an antiemetic (used to prevent chemotherapy-induced nausea and vomiting). A “rolapitant synthesis” patent typically refers to a patent that claims a method for making rolapitant—covering steps, reagents, reaction conditions, purification or crystallization processes, or specific intermediates used in the manufacturing route. Such patents protect the manufacturing method more than the finished drug itself, unless the patent also includes product/process claims tied to the drug and its intermediates.
Because “US” is part of your question, it likely means you want the corresponding United States patent(s) covering rolapitant manufacturing/synthesis.
Which specific U.S. patents cover rolapitant manufacturing or synthesis?
To identify the exact U.S. patent numbers, I need one of the following from you:
- the assignee/company name (e.g., the holder of the rolapitant synthesis patent), or
- the patent application number or publication number (US…A1 / US…B2), or
- a link to the patent page you’re looking at, or
- the title/abstract text you saw (even a short snippet).
If you paste any of that, I can map it to the exact U.S. patent(s) and tell you what the claims cover (method steps vs intermediates vs solid forms).
When does the U.S. rolapitant synthesis patent expire (and what could extend it)?
Patent expiration depends on:
- the filing date (utility patents generally expire about 20 years from the earliest non-provisional filing, subject to adjustments),
- any patent term adjustments (PTA),
- any patent term extensions (PTE) tied to regulatory approval (often relevant to branded drugs),
- and whether there are multiple related continuations or separate patents in the same family.
Method-of-synthesis patents often run alongside other protection (composition-of-matter, formulation, intermediates, polymorph/solid form). Even if a synthesis-method patent expires, other patents may still block generic manufacturing or sale if they cover key aspects like the active ingredient or its form.
Can companies make rolapitant in the U.S. without infringing a “synthesis” patent?
They may be able to if they:
- use a manufacturing route that avoids every claimed step/condition/intermediate in the patent’s independent claims, or
- work outside the claimed ranges or conditions,
- or rely on a different patent coverage landscape (for example, if the synthesis-method patent is narrower than the generic manufacturing process).
In practice, generic and biosimilar developers conduct “freedom-to-operate” analyses because even a small claim overlap (an intermediate, a crystallization step, a purification method) can create infringement risk.
What’s the difference between a synthesis-method patent and a composition-of-matter patent for rolapitant?
A synthesis-method patent typically claims “how to make” rolapitant (process steps, conditions, intermediates).
A composition-of-matter patent claims the drug substance itself (and sometimes specific solid forms/polymorphs/salts).
For market access, composition-of-matter patents are often the biggest barrier; method patents can be narrower but still matter for manufacturing.
What should you look for in the U.S. patent text?
If you’re trying to interpret “synthesis patent” scope, the key places are:
- claim 1 (or the independent claims) to see exactly which steps are required,
- definitions in the specification (intermediates, reagents, stoichiometries, temperatures),
- examples (often show embodiments but claim language controls),
- dependent claims (they narrow the method further, which can matter for design-arounds).
Next step: send the patent identifier you have
Reply with any one of the following and I’ll return the exact U.S. rolapitant synthesis patent(s), what they claim, and their expiration mechanics:
- US publication number (e.g., “US 20xx/xxxxxxx A1”), or
- US patent number (e.g., “US x,xxx,xxx”), or
- assignee/company name, or
- a link or screenshot text from the patent page you found.
Sources
No sources were provided in your message, so I can’t cite specific U.S. rolapitant synthesis patents yet.